From clinical trials to evidence-based medicine: How to build the evidence!

European Journal of Cancer, Supplement

Volumn 1, Issue 6 SPEC. ISS., 2003, Pages 55-65

  Therasse, Patrick ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; MAXIMUM TOLERATED DOSE; META ANALYSIS; MORBIDITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT;

EID: 5144235533     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)90010-3     Document Type: Conference Paper

References (31)

1. Fervers B., Bey P., Maigne D., Philip T. Standards, options and recommendations: a multidisciplinary program to promote evidence-based oncology. Bull Cancer. 88:2001;601-604
2. Sackett D.L., Rosenberg W.M.C., Muir Gray J.A., Haynes R.B., Richardson W.S. Evidence based medicine: what it is and what it isn't. BMJ. 312:Jan 1996;71-72
3. Badenoch D., Heneghan C. Evidence-based medicine toolkit. BMJ Books. 2002;50-54 BMJ Publishing Group, London
4. Guyatt G.H., Sackett D.L., Sinclair J.C., Hayward R., Cook D.J., Cook R.J. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA. 274:Dec 1995;1800-1804
5. Harbour R., Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 323:Aug 2001;334-336
6. Imadalou K., Cvitkovic E. Phase III trials in oncology. Bull Cancer. 86:1999;143-147
7. Cox J.D. Evidence in oncology. The Janeway lecture 2000. Cancer J. 6:Nov-Dec 2000;351-357
8. Djulbegovic B., Loughran T.P. Jr, Hornung C.A., et al. The quality of medical evidence in hematology-oncology. Am J Med Feb. 106:1999;198-205
9. Brooks A.D., Sulimanoff I. Evidence-based oncology project. Surg Oncol Clin N Am. 11:Jan 2002;3-10
10. Brooks A.D., Sulimanoff I. Evidence-based oncology project. Surg Oncol Clin N Am. 11:Jan 2002;vii
11. Brooks A.D., Karpoff H.M., Sulimanoff I., Coit D., Brennan M.F., Jacques D.P. The search for level I evidence in solid-tumor oncology. Ann Surg Oncol. 8:Sept 2001;638-643
12. Grimes D.A., Schulz K.F. An overview of clinical research: the lay of the land. Lancet. 359:Jan 2002;57-61. Review
13. Tannock I.F. Collaborative clinical trials: quality or quantity? Int J Radiat Oncol Biol Phys. 49:Feb 2001;339-343
14. Hortobagyi G.N. High-dose chemotherapy for primary breast cancer: facts versus anecdotes. J Clin Oncol. 17:1999;25-29. (Nov Suppl)
15. Van Glabbeke M., Steward W., Armand J.P. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer. 38:2002;635-638
16. Miller T.P., Dahlberg S. Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by South west Oncology Group. Cancer Treat Res. 66:1993;53-63
17. Stenning S.P., Parmar M.K.B. Designing randomised trials: both large and small trials are needed. Ann Oncol. 13:2002;131-138
18. Parmar M.K., Ungerleider R.S., Simon R. Assessing whether to perform a confirmatory randomised clinical trial. J Natl Cancer Inst Nov. 88:1996;1645-1651
19. Piccart M.J., Bertelsen K., James K., et al. Randomised Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 92:May 2000;699-708
20. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:Jan 1996;1-6
21. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomised study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 18:Jan 2000;106-115
22. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 360:Aug 2002;505-515
23. Moss C., Kaye S.B. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer. 38:Sep 2002;1701-1707
24. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet. 355:March 2000;1041-1047
25. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 343:Sep 2000;905-914
26. Mayer R.J. Moving beyond fluorouracil for colorectal cancer. N Engl J Med. 343:Sep 2000;963-964
27. Sylvester R.J., Collette L., Duchateau L. The role of meta-analyses in assessing cancer treatments. Eur J Cancer. 36:Jul 2000;1351-1358. Review
28. Parmar M.K.B., Stewart L.A., Altman D.G. Meta-analyses of randomised trials: when the whole is more than just the sum of the parts. Br J Cancer. 74:Aug 1996;496-501
29. Sylvester R.J., van der Meijden A.P.M., Lamm D.L. Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomised clinical trials. J Urol. 168:Nov 2002;1964-1970
30. Williams C.J. Evidence-based cancer care. Clin Oncol (R Coll Radiol). 10:1998;144-149
31. Browman G.P. Evidence-based paradigms and opinions in clinical management and cancer research. Semin Oncol. 26:Jun 1999;9-13